Immunovant, Inc.
IMVT
$31.46
-$0.15-0.48%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -33.64% | 12.54% | -4.88% | -13.31% | 4.21% |
| Total Depreciation and Amortization | -4.95% | -3.81% | -1.87% | -1.83% | 10.10% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -12.35% | -4.80% | -27.80% | 58.29% | 0.29% |
| Change in Net Operating Assets | 659.44% | -47.91% | 168.01% | 3.54% | -1,434.61% |
| Cash from Operations | -2.96% | 9.94% | 12.69% | -6.12% | -10.21% |
| Capital Expenditure | -- | -- | -- | -- | -11.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -11.67% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -99.37% | 2,197.98% | 742.87% | -99.35% | 18,200.77% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 113.99% | -- | -- | -- | -- |
| Cash from Financing | -99.36% | 2,195.60% | 742.87% | -99.35% | 18,187.82% |
| Foreign Exchange rate Adjustments | -362.07% | -57.06% | 255.12% | -15.98% | -227.52% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -119.55% | 713.50% | 33.04% | -133.91% | 445.31% |